No Detail Found!

Biological composition, efficacy and primary efficacy endpoint of SARS-CoV-2 vaccines: A special communication

Author(s)
Imran Ishaque Department of Anatomy, United Medical and Dental Collage, Jinnah Sindh Medical University, Karachi, Pakistan
Muhammad Muhib United Medical and Dental College,Karachi,Pakistan
Omer Bin Khalid Jamil Department of Surgery, United Medical and Dental Collage,Karachi,Pakistan
Abstract
Severe acute respiratory syndrome coronavirus 2 was fi rst reported in Wuhan, China, in late December 2019 and rapidly spread out globally, affecting 130 million individuals and starting a global pandemic. An efficacious vaccine is considered an essential tool to reduce mortality and morbidity rate related to the pandemic. Nine different vaccine candidates announced the efficacy results of their respective phase 3 trial testing up till January 2021. By the end of June 2021, the administration of seven different vaccines started under the supervision of the World Health Organisation. The current article was planned to discuss the biological composition, efficacy and primary efficacy endpoint described in literature, and to identify the factors that could affect vaccine efficacy and vaccine coverage.
Publication Details
Page(s) 2264-2269
Published Journal: Journal of Pakistan Medical Association, Volume: 72, Issue: 11, Year: 2022

Request the full text from PASTIC

Keywords
Efficacy, Factors, SARS-CoV-2 Vaccine, Efficacy endpoint, Vaccine coverage
0

Citations

0

Downloads

92

Views